Home/Pipeline/PS-102

PS-102

Hematological Malignancies

PreclinicalActive

Key Facts

Indication
Hematological Malignancies
Phase
Preclinical
Status
Active
Company

About Perimeter Systems, Inc.

Developing precision gene therapy delivery platforms for oncology with enhanced tumor targeting and reduced off-target effects.

View full company profile

Therapeutic Areas

Other Hematological Malignancies Drugs

DrugCompanyPhase
NP-G2-044Novita PharmaceuticalsPhase 2a
JaxBio Hematology Cancer TestJaxBioPreclinical